UBS (Lux) Equity Fund - Biotech (USD) (EUR) Q-acc

Register to Unlock Ratings
Performance History30/04/2024
Growth of 1,000 (GBP) Advanced Graph
UBS (Lux) Equity Fund - Biotech (USD) (EUR) Q-acc
Fund-----8.1
+/-Cat-----4.3
+/-B’mrk-----14.6
 
Key Stats
NAV
08/05/2024
 EUR 97.29
Day Change 0.32%
Morningstar Category™ Sector Equity Biotechnology
ISIN LU1769088235
Fund Size (Mil)
08/05/2024
 USD 470.85
Share Class Size (Mil)
08/05/2024
 EUR 0.02
Max Initial Charge 5.00%
Ongoing Charge
31/12/2023
  1.08%
Investment Objective: UBS (Lux) Equity Fund - Biotech (USD) (EUR) Q-acc
The Fund’s investment objective consists in generating strong capital appreciation with a reasonable level of income, while giving due consideration to capital security and the liquidity of the Fund’s assets. UBS Asset Management categorises this sub-fund as an ESG Integration fund that does not promote particular ESG characteristics or pursues a specific sustainability or impact objective. The sub-fund mainly invests in shares and other equity interests of companies focusing on research, product development, product manufacture and distribution in the biotechnology industry and related sectors. The investments can be made in equities and equity interests of large multinationals or other companies whose products are not yet ready for marketing. Investments are made worldwide without restrictions. For the aforementioned reasons, units in this sub-fund may occasionally exhibit substantial price fluctuations.
Returns
Trailing Returns (GBP)08/05/2024
YTD-2.26
3 Years Annualised-
5 Years Annualised-
10 Years Annualised-
12 Month Yield 0.00
Management
Manager Name
Start Date
Sara Cotter
01/10/2022
Matthew Konosky
01/10/2017
Inception Date
03/01/2023
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
MSCI US IMI/BIOTECHNOLOGY 10/40 NR USDMorningstar Gbl Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNot Specific
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  UBS (Lux) Equity Fund - Biotech (USD) (EUR) Q-acc31/03/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock99.580.0099.58
Bond0.000.000.00
Property0.000.000.00
Cash0.930.510.42
Other0.000.000.00
Top 5 Regions%
United States86.83
Europe - ex Euro7.44
Eurozone4.40
United Kingdom1.33
Canada0.00
Top 5 Sectors%
Healthcare98.19
Basic Materials1.81
Top 5 HoldingsSector%
Moderna IncHealthcareHealthcare9.89
Vertex Pharmaceuticals IncHealthcareHealthcare9.45
Regeneron Pharmaceuticals IncHealthcareHealthcare9.35
Alnylam Pharmaceuticals IncHealthcareHealthcare6.92
AbbVie IncHealthcareHealthcare4.71
UBS (Lux) Equity Fund - Biotech (USD) (EUR) Q-acc

Related

In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures